{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T13:51:37Z","timestamp":1781617897850,"version":"3.54.5"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To study the clinical efficacy of infliximab (IFX) in combination with mesalazine in patients with Crohn\u2019s disease (CD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective analysis study included 197 patients with CD who were treated in Haiyan People's Hospital and Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University our hospital between March 2023 and March 2024, and were divided into two groups according to the different treatments recorded in the electronic medical record system: 82 cases in the control group (mesalazine) and 115 cases in the observation group (IFX combined with mesalazine treatment). The intestinal flora (bifidobacteria, Lactobacillus, Enterococcus, Enterobacteriaceae), serum indicators (tumor necrosis factor-\u03b1 (TNF-\u03b1), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), hemoglobin concentration (HGB), platelets (PLT), Th1, Th2, Th1\/Th2), major symptoms and stool status (disappearance of abdominal pain, disappearance of diarrhea, stool frequency and stool normalization), clinical efficacy and complication situation were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The number of bifidobacteria and lactobacilli in the observation group was higher than that in the control group, and the difference was statistically significant (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05); TNF-\u03b1, CRP, ESR, PLT, Th1 and Th1\/Th2 were lower than those in the control group, but HGB and Th2 were higher than those in the control group, and the difference was statistically significant (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05); After treatment, the rate of abdominal pain disappearance, diarrhea disappearance and normal stool rate were higher than that of the control group, and the number of stools was lower than that of the control group, with statistically significant differences (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05); the total clinical effective rate of the observation group (92.17% vs. 80.49%) was higher than that of the control group, with statistically significant difference (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05); the overall incidence rate of adverse reactions of the observation group (8.70% vs. 7.32%) was higher than that of the control group, but the difference was not statistically significant (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&gt;\u20090.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>IFX combined with mesalazine demonstrates superior clinical efficacy compared to mesalazine monotherapy in patients with Crohn\u2019s disease. This combination effectively improves intestinal microbiota balance, reduces inflammation, modulates immune responses, and alleviates clinical symptoms without significantly increasing adverse events.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12876-025-04236-9","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T17:13:25Z","timestamp":1759166005000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Therapeutic regimen of Crohn\u2019s disease: effect of Infliximab combined with mesalazine on intestinal flora and inflammatory indexes in patients"],"prefix":"10.1186","volume":"25","author":[{"given":"Xiaoxia","family":"Xiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenghua","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyuan","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"issue":"2","key":"4236_CR1","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s10620-023-08182-y","volume":"69","author":"Y Miyatani","year":"2024","unstructured":"Miyatani Y, Choi D, Choi NK, et al. Dual-Targeted therapy with Upadacitinib and ustekinumab in medically complex crohn\u2019s Disease[J]. Dig Dis Sci. 2024;69(2):355\u20139.","journal-title":"Dig Dis Sci"},{"issue":"S1","key":"4236_CR2","doi-asserted-by":"publisher","first-page":"S77","DOI":"10.1097\/DCR.0000000000002547","volume":"65","author":"S Akiyama","year":"2022","unstructured":"Akiyama S, Dyer EC, Rubin DT. Diagnostic and Management Considerations for the IPAA With Crohn\u2019s Disease-Like Features. Dis Colon Rectum. 2022;65(S1):S77-84.","journal-title":"Dis Colon Rectum"},{"issue":"6","key":"4236_CR3","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1093\/ecco-jcc\/jjad008","volume":"17","author":"S Cao","year":"2023","unstructured":"Cao S. Colonna m,deepak p.pathogenesis of perianal fistulising crohn\u2019s disease:current knowledge,gaps in understanding,and future research Directions[J]. J Crohns Colitis. 2023;17(6):1010\u201322.","journal-title":"J Crohns Colitis"},{"issue":"5","key":"4236_CR4","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1093\/ecco-jcc\/jjab211","volume":"16","author":"S Honap","year":"2022","unstructured":"Honap S, Meade S, Spencer A, et al. Anogenital Crohn\u2019s Disease and Granulomatosis: A Systematic Review of Epidemiology, Clinical Manifestations, and Treatment. J Crohns Colitis. 2022;16(5):822\u201334.","journal-title":"J Crohns Colitis"},{"issue":"1","key":"4236_CR5","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3390\/nu13010212","volume":"13","author":"CM Verburgt","year":"2021","unstructured":"Verburgt CM, Ghiboub M, Benninga MA, et al. Nutritional therapy strategies in pediatric crohn\u2019. S Disease[J] Nutrients. 2021;13(1):212.","journal-title":"S Disease[J] Nutrients"},{"issue":"48","key":"4236_CR6","doi-asserted-by":"publisher","first-page":"8201","DOI":"10.3748\/wjg.v27.i48.8201","volume":"27","author":"WX Cheng","year":"2021","unstructured":"Cheng WX, Ren Y, Lu MM, et al. Palmitoylation in crohn\u2019s disease:current status and future directions[J]. World J Gastroenterol. 2021;27(48):8201\u201315.","journal-title":"World J Gastroenterol"},{"issue":"11","key":"4236_CR7","first-page":"CD012623","volume":"11","author":"M Gordon","year":"2023","unstructured":"Gordon M, Sinopoulou V, Akobeng AK, et al. Infliximab for medical induction of remission in crohn\u2019s disease[J]. Cochrane Database Syst Rev. 2023;11(11):CD012623.","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"4236_CR8","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/S2468-1253(20)30117-5","volume":"5","author":"TW Stevens","year":"2020","unstructured":"Stevens TW, Haasnoot ML,D\u2019Haens GR, et al. LIR!C study group.laparoscopic ileocaecal resection versus Infliximab for terminal ileitis in crohn\u2019s disease:retrospective long-term follow-up of the LIR!C trial[J]. Lancet Gastroenterol Hepatol. 2020;5(10):900\u20137.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"4236_CR9","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S2468-1253(22)00385-5","volume":"8","author":"E Louis","year":"2023","unstructured":"Louis E, Resche-Rigon M, Laharie D, et al. GETAID and the SPARE-Biocycle research group.withdrawal of Infliximab or concomitant immunosuppressant therapy in patients with crohn\u2019s disease on combination therapy(SPARE):a multicentre,open-label,randomised controlled trial[J]. Lancet Gastroenterol Hepatol. 2023;8(3):215\u201327.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"4236_CR10","doi-asserted-by":"crossref","unstructured":"Jhakri K, Al-Shudifat M, Sumra B, Kocherry C, Shamim H, Mohammed L. Mesalazine-Induced Myocarditis in Inflammatory Bowel Disease: A Systematic Review. Cureus. 2025 Jan 29;17(1):e78208","DOI":"10.7759\/cureus.78208"},{"issue":"43","key":"4236_CR11","doi-asserted-by":"publisher","first-page":"6891","DOI":"10.3748\/wjg.v26.i43.6891","volume":"26","author":"R Rajbhandari","year":"2020","unstructured":"Rajbhandari R, Blakemore S, Gupta N, et al. Crohn\u2019s disease in low and lower-middle income countries:a scoping review[J]. World J Gastroenterol. 2020;26(43):6891\u2013908.","journal-title":"World J Gastroenterol"},{"key":"4236_CR12","doi-asserted-by":"crossref","unstructured":"Loras C. Ma\u00f1osa M, And\u00fajar X, En representaci\u00f3n de GETECCU. Position Statement. Recommendations of the Spanish Group on Crohn\u2019s Disease and Ulcerative Colitis(GETECCU)on the treatment of strictures in Crohn\u2019s disease. Gastroenterol Hepatol 2022;45(4):315\u201334.","DOI":"10.1016\/j.gastre.2022.04.002"},{"issue":"1","key":"4236_CR13","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s13148-021-01089-3","volume":"13","author":"M Hornschuh","year":"2021","unstructured":"Hornschuh M, Wirthgen E,Wolfien M, et al. The role of epigenetic modifications for the pathogenesis of crohn\u2019s disease[J]. Clin Epigenetics. 2021;13(1):108.","journal-title":"Clin Epigenetics"},{"issue":"10","key":"4236_CR14","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1016\/j.chom.2022.08.002","volume":"30","author":"J Gao","year":"2022","unstructured":"Gao J, Zhao X, Hu S, et al. Gut microbial DL-endopeptidase alleviates Crohn\u2019s disease via the NOD2 pathway. Cell Host Microbe. 2022;30(10):1435-e14499.","journal-title":"Cell Host Microbe"},{"issue":"2","key":"4236_CR15","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1053\/j.gastro.2023.08.047","volume":"166","author":"Z Li","year":"2024","unstructured":"Li Z, Chen Y, Ke H. Investigating the Causal Relationship Between Gut Microbiota and Crohn\u2019s Disease: A Mendelian Randomization Study. Gastroenterology. 2024;166(2):354\u20135.","journal-title":"Gastroenterology"},{"issue":"6","key":"4236_CR16","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00535-021-01784-1","volume":"56","author":"Hiroshi Nakase","year":"2021","unstructured":"Nakase Hiroshi, Uchino Motoi, Shinzaki Shinichiro, et al. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. J Gastroenterol. 2021;56(6):489\u2013526.","journal-title":"J Gastroenterol"},{"issue":"10182","key":"4236_CR17","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1016\/S0140-6736(18)32778-8","volume":"393","author":"Krisztina Gecse","year":"2019","unstructured":"Gecse Krisztina, D\u2019Haens Geert R. Infliximab biosimilar CT-P13 in Crohn\u2019s disease. Lancet. 2019;393(10182):1671\u20132.","journal-title":"Lancet"},{"issue":"1","key":"4236_CR18","doi-asserted-by":"publisher","first-page":"S444","DOI":"10.14309\/01.ajg.0000592588.04875.5e","volume":"114","author":"O Camilo","year":"2019","unstructured":"Camilo O. Zhijie Ding, James Izanec, 763 Relationship Between Crohn\u2019s Disease Activity Index and Patient-Reported Outcomes for Crohn\u2019s Disease Patients in the United States. Am J Gastroenterol. 2019;114(1):S444-5.","journal-title":"Am J Gastroenterol"},{"key":"4236_CR19","doi-asserted-by":"crossref","unstructured":"Young DD, Perry S, Malay S, Sferra TJ, Finkler M, Moses J. Natural History of Pediatric Patients With Crohn's Disease Treated With Mesalamine Therapy. JPGN Rep. 2023 Nov 3;4(4):e379","DOI":"10.1097\/PG9.0000000000000379"},{"issue":"1","key":"4236_CR20","doi-asserted-by":"publisher","first-page":"2297565","DOI":"10.1080\/08941939.2023.2297565","volume":"37","author":"M Shen","year":"2024","unstructured":"Shen M, Shi Y,Ge Z, et al. Effects of Mesalamine combined with live combined bifidobacterium,lactobacillus and Enterococcus capsules on intestinal mucosa barrier function and intestinal microbiota in mildly active crohn\u2019s disease Patients[J]. J Invest Surg. 2024;37(1):2297565.","journal-title":"J Invest Surg"},{"key":"4236_CR21","doi-asserted-by":"crossref","unstructured":"Xu S, Li X, Zhang S, Qi C, et al. Oxidative stress gene expression, DNA methylation, and gut microbiota interaction trigger Crohn's disease: a multi-omics Mendelian randomization study. BMC Med. 2023 May 11;21(1):179","DOI":"10.1186\/s12916-023-02878-8"},{"issue":"3","key":"4236_CR22","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1002\/jgh3.12259","volume":"4","author":"T Chiba","year":"2019","unstructured":"Chiba T, Endo M, Miura S, et al. Regulatory T cells in Crohn\u2019s disease following anti-TNF-\u03b1therapy. JGH Open. 2019;4(3):378\u201381.","journal-title":"JGH Open"},{"issue":"8","key":"4236_CR23","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1093\/ecco-jcc\/jjad133","volume":"18","author":"S Lin","year":"2024","unstructured":"Lin S, Hannon E,Reppell. M,et al.whole blood DNA methylation changes are associated with Anti-TNF drug concentration in patients with crohn\u2019s Disease[J]. J Crohns Colitis. 2024;18(8):1190\u2013201.","journal-title":"J Crohns Colitis"},{"key":"4236_CR24","doi-asserted-by":"crossref","unstructured":"Otake H, Matsumoto S. Mashima H.Long-term clinical and real-world experience with Crohn\u2019s disease treated with anti-tumor necrosis factor-\u03b1antibodies. Intest Res 2022,20(4):464\u201374.","DOI":"10.5217\/ir.2021.00139"},{"key":"4236_CR25","doi-asserted-by":"crossref","unstructured":"Young DD, Perry S, Malay S, Sferra TJ, Finkler M, Moses J. Natural History of Pediatric Patients With Crohn's Disease Treated With Mesalamine Therapy. JPGN Rep. 2023 Nov 3;4(4):e379","DOI":"10.1097\/PG9.0000000000000379"},{"issue":"1","key":"4236_CR26","doi-asserted-by":"publisher","first-page":"21353","DOI":"10.1038\/s41598-020-78603-9","volume":"10","author":"S Tamura","year":"2020","unstructured":"Tamura S, Ishida N, Miyazu T, et al. Mesalazine granule formulation improves clinical data in crohn\u2019s disease compared with tablet formulation[J]. Sci Rep. 2020;10(1):21353.","journal-title":"Sci Rep"},{"key":"4236_CR27","doi-asserted-by":"crossref","unstructured":"Pierre N, Huynh-Thu VA, Baiwir D et al. GETAID and the SPARE-Biocycle research group. External validation of serum biomarkers predicting short-term and mid\/long-term relapse in patients with Crohn\u2019s disease stopping infliximab. Gut, 2024,73(12):1965\u201373.","DOI":"10.1136\/gutjnl-2024-332648"},{"issue":"14","key":"4236_CR28","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.3748\/wjg.v26.i14.1554","volume":"26","author":"XL Sun","year":"2020","unstructured":"Sun XL, Chen SY, Tao SS, et al. Optimized timing of using Infliximab in perianal fistulizing crohn\u2019s disease[J]. World J Gastroenterol. 2020;26(14):1554\u201363.","journal-title":"World J Gastroenterol"},{"issue":"8","key":"4236_CR29","first-page":"EVIDoa2200061","volume":"1","author":"S Buhl","year":"2022","unstructured":"Buhl S, Steenholdt C, Brynskov J, et al. Discontinuation of Infliximab therapy in patients with crohn\u2019s. Disease[J] NEJM Evid. 2022;1(8):EVIDoa2200061.","journal-title":"Disease[J] NEJM Evid"},{"issue":"1","key":"4236_CR30","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s00384-023-04378-w","volume":"38","author":"B Han","year":"2023","unstructured":"Han B, Tang D, Lv X, et al. Comparative efficacy and safety of combination therapy with Infliximab for crohn\u2019s disease:a systematic review and network meta-analysis[J]. Int J Colorectal Dis. 2023;38(1):82.","journal-title":"Int J Colorectal Dis"},{"issue":"1","key":"4236_CR31","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40360-021-00520-y","volume":"22","author":"D Dubrall","year":"2021","unstructured":"Dubrall D, Leitzen S, Toni I, et al. Descriptive analysis of adverse drug reaction reports in children and adolescents from germany:frequently reported reactions and suspected drugs[J]. BMC Pharmacol Toxicol. 2021;22(1):56.","journal-title":"BMC Pharmacol Toxicol"},{"issue":"7","key":"4236_CR32","doi-asserted-by":"publisher","first-page":"CD013611","DOI":"10.1002\/14651858.CD013611.pub2","volume":"7","author":"S Hui","year":"2023","unstructured":"Hui S, Sinopoulou V, Gordon M, et al. Vedolizumab for induction and maintenance of remission in crohn\u2019s disease. Cochrane Database Syst Rev. 2023;7(7):CD013611. https:\/\/doi.org\/10.1002\/14651858.CD013611.pub2.","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"4236_CR33","doi-asserted-by":"publisher","first-page":"CD011806","DOI":"10.1002\/14651858.CD011806.pub2","volume":"10","author":"C Wallace","year":"2023","unstructured":"Wallace C, Gordon M, Sinopoulou V, Limketkai BN. Vitamin D for the treatment of inflammatory bowel disease. Cochrane Database Syst Rev. 2023;10(10):CD011806. https:\/\/doi.org\/10.1002\/14651858.CD011806.pub2.","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"4236_CR34","doi-asserted-by":"publisher","first-page":"CD015084","DOI":"10.1002\/14651858.CD015084.pub2","volume":"3","author":"V Sinopoulou","year":"2024","unstructured":"Sinopoulou V, Gordon M, Gregory V, Saadeh A, Akobeng AK. Prebiotics for induction and maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2024;3(3):CD015084. https:\/\/doi.org\/10.1002\/14651858.CD015084.pub2.","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"4236_CR35","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1136\/gutjnl-2024-332489","volume":"73","author":"S Honap","year":"2024","unstructured":"Honap S, Jairath V, Sands BE, Dulai PS, Danese S, Peyrin-Biroulet L. Acute severe ulcerative colitis trials: the past, the present and the future. Gut. 2024;73(10):1763\u201373. https:\/\/doi.org\/10.1136\/gutjnl-2024-332489.","journal-title":"Gut"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04236-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-025-04236-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04236-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T12:53:41Z","timestamp":1781614421000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12876-025-04236-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4236"],"URL":"https:\/\/doi.org\/10.1186\/s12876-025-04236-9","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,29]]},"assertion":[{"value":"7 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of Haiyan People\u2019s Hospital (IRB No. 52336). Given that this study was retrospective and only de-identified patient data were used, so Haiyan People\u2019s Hospital and Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University waived the need for informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"687"}}